0001093557-21-000177.txt : 20210708
0001093557-21-000177.hdr.sgml : 20210708
20210708194551
ACCESSION NUMBER: 0001093557-21-000177
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210706
FILED AS OF DATE: 20210708
DATE AS OF CHANGE: 20210708
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Balo Andrew K
CENTRAL INDEX KEY: 0001323190
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51222
FILM NUMBER: 211081374
MAIL ADDRESS:
STREET 1: C/O DEXCOM, INC.
STREET 2: 5555 OBERLIN DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: DEXCOM INC
CENTRAL INDEX KEY: 0001093557
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 330857544
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6340 SEQUENCE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 8582000200
MAIL ADDRESS:
STREET 1: 6340 SEQUENCE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2021-07-06
0
0001093557
DEXCOM INC
DXCM
0001323190
Balo Andrew K
6340 SEQUENCE DRIVE
SAN DIEGO
CA
92121
0
1
0
0
*
Common Stock
2021-07-06
4
S
0
578
428.5056
D
15805
I
by Trust
Common Stock
2021-07-06
4
S
0
400
429.331
D
15405
I
by Trust
Common Stock
2021-07-06
4
S
0
1710
430.5576
D
13695
I
by Trust
Common Stock
2021-07-06
4
S
0
286
432.0479
D
13409
I
by Trust
Common Stock
16533
D
On March 5, 2021, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan.
This transaction was executed in multiple trades at prices ranging from $428.125 to $429.060. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee.
This transaction was executed in multiple trades at prices ranging from $429.141 to $429.401. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected.
This transaction was executed in multiple trades at prices ranging from $430.270 to $430.919. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected.
This transaction was executed in multiple trades at prices ranging from $431.455 to $432.050. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issurer full information regarding the number of shares and prices at which the transactions were effected.
*EVP Regulatory Strategy Clinical Affairs and Strategic Partnership Development
By: Jereme Sylvain For: Andrew K Balo
2021-07-08